2017 Annual General Meeting: Shareholders approve all proposals
Dietlikon, 22 March 2017– Implenia Ltd.’s Annual General Meeting of Shareholders has approved all of the Board of Directors’ proposals. Among other things, shareholders approved payment of an ordinary dividend of CHF 2.00 per share (previous year: CHF 1.80, plus CHF 0.10 anniversary dividend). The AGM also discharged the Members of the Board of Directors and Group Executive Board for their actions in 2016 and approved the 2016 Remuneration Report in a consultative vote.
After serving four years on the Board, Vice Chairman Calvin Grieder did not stand for re-election. The Board of Directors and Executive Board would like to thank him very much for his valuable contribution to Implenia’s success. Current Board Members Hans Ulrich Meister (Chairman), Chantal Balet Emery, Kyrre Olaf Johansen, Henner Mahlstedt, Ines Pöschel and Laurent Vulliet were confirmed in their posts for a further term.
Implenia press contact:
Reto Aregger
Head of Communications Group
Tel.: +41 58 474 74 77
Implenia is Switzerland’s leading construction and construction services company. It also has strong positions in the German, Austrian and Scandinavian infrastructure markets. Established in 2006, Implenia can look back on around 150 years of construction tradition. It brings the expertise of its highly skilled sectoral and regional units together under the roof of a company active throughout Europe. With its integrated business model and specialists operating in all areas of construction, the Group can manage a building project through its entire lifecycle and deliver work that is economical, integrated and customer-centric. The focus is on striking a sustainable balance between financial success and social and environmental responsibility.
Implenia, with its headquarters in Dietlikon near Zurich, currently employs more than 8,200 people around Europe and posted revenue of around CHF 3.3 billion in 2016. The company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). More information can be found at www.implenia.com.
